Effect of Indoleamine 2,3 Dioxygenase Inhibitor on the Cytotoxic Activity of Tumour-infiltrating Lymphocytes

Sarah LE NAOUR1, Anne-Chantal KNOL1, Marie-Christine PANDOLFINO2, Amir KHAMMARI1 and Brigitte DRÉNO1,2

1Dermato-Cancerology Department, CHU Nantes, CIC1413, CRCINA, University Nantes, Place Alexis Ricordeau, FR-44093 Nantes, and 2Cell and Gene Therapy Unit, CHU Nantes, Nantes, France. E-mail: brigitte.dreno@atlanmed.fr

Accepted Aug 12, 2019; E-published Aug 13, 2019

There have been major therapeutic advances in the treatment of melanoma in recent years (1, 2). Adoptive T-cell therapy, based on tumour-infiltrating lymphocytes (TILs) obtained from tumour tissues, has been developed in the field of immunotherapy. An objective clinical response of between 40% and 72% in the metastatic stage has been reported (3, 4) but the clinical response remains limited in time. In the metastatic stage of melanoma, the clinical response remains limited and short-term. A major current challenge is to increase the efficacy of TILs by countering the immune tolerance of the tumour microenvironment through identification of the molecules implicated in this phenomenon. Many factors have been suggested, including indoleamine 2,3 dioxygenase (IDO), an intracellular enzyme that metabolizes tryptophan to kynurenine. Tryptophan deficiency inhibits the activity and proliferation of T cells (5). A recent paper (6) has shown that IDO1 expression in metastatic melanoma lymph nodes is associated with an increased risk of relapse and death. Thus, we hypothesize that the presence of IDO in the tumour microenvironment could inhibit the activity of TILs, and that adding an IDO inhibitor to the TILs could increase their cytotoxic activity against melanoma cells.

MATERIAL AND METHODS

To investigate this hypothesis we used the model of co-culture of a melanoma cell-line and autologous TILs obtained from the same patient (6), with the addition of IDO inhibitor. The endpoints were the frequency of reactive autologous T cells among the TILs and the expression of molecules involved in the recognition of tumour antigens by T cells with and without IDO inhibitor. Melanoma cells were derived from patients with metastatic melanoma, who were previously included in several distinct clinical trials of TILs (7–10). Seven tumour cell-lines with associated autologous TILs were selected (4 wild-type cell-lines and 3 cell-lines with positive BRAF mutational status, but no difference according this mutational status was noted).

In a first step, the 7 melanoma cell-lines were incubated either with an IDO inhibitor, 1-methyl-L-tryptophan (1-MT) (in 2 different concentrations), alone or after incubation with interferon gamma (INF-γ) for mimicking the chronic inflammatory microenvironment state of a metastasis (associated with an increase in immune tolerance). In a second step, the 7 melanoma cells were distributed on a 96-well plate (300,000 cells per well) with 100,000 autologous TILs. Co-cultures were incubated for 6 h at 37°C, 5% CO₂. Finally, melanoma cells were analysed by flow cytometry for expression of IDO1, MHC-I, MHC-II and PD-L1 antigens and reactivity of TILs by a double-labelling: membrane CD3 and intracellular interferon (IFN)-γ. The data were analysed using CellQuestPro® software. Tryptophan and kynurenine levels were determined by enzyme-linked immunoassay (ELISA) (ImmunoSmol (BD Biosciences, San Jose, USA)) in order to calculate kynurenine/tryptophan ratios.

RESULTS

In the basal state (without INF-γ), IDO1 expression was shown for 5 melanoma cell-lines (Fig. 1a). MHC-I was expressed by all the cell-lines. MHC-II was expressed by only 4 cell-lines. No expression of PD-L1 was noted in any of the 7 cell-lines. Intracytoplasmic expression of IFN-γ by TILs was very low in the basal state. Adding the IDO inhibitor decreased the expression of IDO1 in a dose-dependent manner (Fig. 1a). For both MHC-I and MHC-II, IDO inhibitor increased their expression in a dose-dependent manner (Fig. 1b, c). No effect on the cytotoxic activity of TILs was found by adding IDO inhibitor (Fig. 2). The absence of expression of IDO1 by 2 melanoma cell-lines is in agreement with a recent paper showing that not all melanoma metastases express IDO (11).

In the inflammatory state (induced by INF-γ), IDO1 was expressed in all melanoma cell-lines: 2 melanoma cell-lines not expressing IDO1 in the basal state, and increased in the other 5 cell-lines in a dose-dependent manner (Fig.
1a). PD-L1 expression was induced in the 7 melanoma cell-lines (Fig. 1d). MHC-I and MHC-II were expressed by all the cell-lines after IFN-γ induction (Fig. 1b, c).

Adding IDO inhibitor decreased expression of IDO1 and PD-L1 in a dose-dependent manner. As in the basal state, MHC-I and MHC-II expression was increased in the presence of IDO inhibitor in a dose-dependent manner. IDO inhibitor in the inflammatory state increased the reactivity of TILs in 2 cell-lines; 1 in a dose-dependent manner (M301, M125) (Fig. 2).

**DISCUSSION**

The results of the current study identify 3 main targets of the IDO inhibitor implicated in lymphocyte-tumour cell interactions. The first 2 targets are MHC-I and MHC-II, whose expression is increased in both basal and inflammatory states. The third target is PD-L1, a ligand of PD-1, whose expression is decreased in the inflammatory state (not expressed at basal state). It has been confirmed that IDO inhibitor stimulates tryptophan degradation activity in a dose-dependent manner (12).

This study also demonstrated that IDO inhibitor can increase the cytotoxic activity of TILs in the inflammatory state, but for only 2 cell-lines. Given that the 2 cell-lines have the same expression profile for CMH-I, CMH-II and PD-L1 than the other 5 cell-lines, this result suggests that mechanisms other than the modulation of MHC-I, MHC-II or PD-L1 by melanoma cells are implicated for increasing the cytotoxicity of TILs by an, as-yet unidentified, IDO inhibitor. These results appear to be consistent with recent clinical trials with IDO inhibitors, in which no benefit was demonstrated, and increase interest in a strategy to define the subgroup of patients who might benefit clinically from this molecule (3).

**ACKNOWLEDGEMENT**

The authors thank the cytometry facility at Cytocell for their expert technical assistance.

_The authors have no conflicts of interest to declare._

**REFERENCES**

1. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol Off J Am Soc Clin Oncol 2009; 27: 6199–6206.

2. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472–492.

3. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 2005; 23: 2346–2357.

4. Saint-Jean M, Knol A-C, Volteau C, Quereux G, Peuvrel L, Brocard A, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in advanced melanoma patients. J Immunol Res 2018; 2018: 3530148.

5. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Melior AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363–1372.

6. Knol AC, Nguyen J-M, Pandolfino M-C, Denis MG, Khammari A, Dréno B. PD-L1 expression by tumor cell lines: a predictive marker in melanoma. Exp Dermatol 2018; 27: 647–655.

7. Dréno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002; 51: 539–546.

8. Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Bercegeay S, et al. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2007; 56: 1853–1860.

9. Khammari A, Knol AC, Nguyen JM, Bossard C, Denis MG, Pandolfino MC, et al. Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res. 2014; 2014: 186212.

10. Khammari A, Nguyen JM, Saint-Jean M, Knol AC, Pandolfino MC, Quereux G, et al. Adoptive T cell therapy combined with intrasplenic administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother 2015; 64: 805–815.

11. Gide TN, Allanson BM, Menzies AM, Ferguson PM, Madore J, Saw RPM, et al. Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment. Histopathology 2019; 74: 817–828.

12. Banzola I, Mengus C, Wyler S, Hudolin T, Manzella G, Chiariugi A, et al. Expression of indoleamine 2,3-dioxygenase induced by IFN-γ and TNF-α as potential biomarker of prostate cancer progression. Front Immunol 2018; 9: 1051.

13. Saini G, Dummer R, Hamid O, Gajewski T, Caglicev C, Dalle S, et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. J Clin Oncol 2018; 36: 108.